Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT01483924 is registered in ClinicalTrials.gov with ApoPharma as lead sponsor.

NCT NCT01483924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01483924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
ApoPharma
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
October 31, 2013
Enrollment
60 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis